Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141191 · ClinicalTrials.gov registry record · Phase 1
A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02141191 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 12 participants.
The verdict
NCT02141191, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether a single overnight, eight-hour administration of a 7% NaCl solution delivered by the Parion Sciences transnasal Pulmonary Aerosol Delivery (tPAD) device has a significant effect on mucociliary clearance in subjects with cystic fibrosis, as compared to no treatment. This study will be conducted at the University of Pittsburgh Medical Center.
Interventions
- DRUG inhaled hypertonic saline (7%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141191
The ClinicalTrials.gov registry entry for NCT02141191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which inhaled hypertonic saline (7%) is the first listed.
NCT02141191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02141191 about?
NCT02141191 is a clinical study titled "A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device". The primary objective of this study is to determine whether a single overnight, eight-hour administration of a 7% NaCl solution delivered by the Parion Sciences transnasal Pulmonary Aerosol Delivery (tPAD) device has a significant effect on mucociliary clearance in subjects with cystic fibrosis, as ...
What is the current status of trial NCT02141191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02141191?
The interventions under investigation include: inhaled hypertonic saline (7%) (DRUG).
Who is sponsoring clinical trial NCT02141191?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.